scholarly journals IL-8 and IL-23 Levels in Peripheral Blood Mononuclear Cells of Patients with Cutaneous Leishmaniasis Caused by Leishmania major: A Case-Control Study

2019 ◽  
Vol 21 (6) ◽  
Author(s):  
Narges Khazaei ◽  
Elham Moghaddas ◽  
Seyed Abdolrahim Rezaee ◽  
Seyed Aliakbar Shamsian
Keyword(s):  
Cutaneous Leishmaniasis ◽  
Peripheral Blood Mononuclear Cells ◽  
Peripheral Blood ◽  
Leishmania Major ◽  
Mononuclear Cells ◽  
Case Control Study ◽  
Case Control ◽  
Peripheral Blood Mononuclear ◽  
Blood Mononuclear Cells ◽  
Control Study

scholarly journals A Novel Leishmania infantum Recombinant Antigen Which Elicits Interleukin 10 Production by Peripheral Blood Mononuclear Cells of Patients with Visceral Leishmaniasis

2000 ◽  
Vol 68 (2) ◽  
pp. 630-636 ◽  
Author(s):  
Isabelle Suffia ◽  
Bernard Ferrua ◽  
Xavier Stien ◽  
Baharia Mograbi ◽  
Pierre Marty ◽  
...  
Keyword(s):  
Visceral Leishmaniasis ◽  
Peripheral Blood Mononuclear Cells ◽  
Peripheral Blood ◽  
Leishmania Infantum ◽  
Leishmania Major ◽  
Mononuclear Cells ◽  
Interleukin 10 ◽  
Immunoglobulin M ◽  
Peripheral Blood Mononuclear ◽  
Blood Mononuclear Cells

ABSTRACT We report here the characterization of a novel Leishmania infantum protein termed papLe22 (22-kDa potentially aggravating protein of Leishmania). A positive clone from a cDNA library was identified by serum of a visceral leishmaniasis (VL) patient. Full-length cDNA obtained using rapid amplification of cDNA ends-PCR codes for a 22-kDa protein. In L. infantumpromastigotes an endogenous nuclear protein of 14-kDa electrophoretic mobility was found by using an antiserum prepared against the fusion protein glutathione S-transferase–papLe22. Its expression was also shown in L. infantum amastigotes and inLeishmania major and Leishmania guyanensispromastigotes. VL patients' sera showed anti-papLe22 immunoglobulin M (IgM) and IgG reactivities, indicating that a primary response against the leishmanial protein papLe22 accompanied acute VL manifestations. Specific IgG levels were correlated with patients' clinical status. The presence of IgG1, IgG2, and IgG3 subclasses suggested a mixed Th1- and Th2-type response; there was no correlation between subclass reactivity and the disease course. The recombinant papLe22 specifically activated interleukin-10 production by VL patients' peripheral blood mononuclear cells collected at diagnosis and after treatment-induced cure, indicating its contribution to VL pathogenesis and concomitant immunosuppression and its potential role in the reactivation of latent parasites. As a dominant immunogen, papLe22 might be used as a vaccine component, provided that the vaccination protocol directs the response toward the Th1 pattern.

Sign in / Sign up

Export Citation Format

Share Document